Bose Prithviraj, Xiao Zhijian, Hasselbalch Hans C, Prchal Josef T, Duan Minghui, Yacoub Abdulraheem, Rampal Raajit, Kiladjian Jean-Jacques, Hobbs Gabriela S, Tashi Tsewang, Shimoda Kazuya, Kirito Keita, Gill Harinder, Hou Hsin-An, Lee Sung-Eun, Huang Jian, Li Bing, Qin Albert, Yu Lennex Hsueh-Lin, Mascarenhas John O, Mesa Ruben A
Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China.
Curr Hematol Malig Rep. 2025 Jul 12;20(1):9. doi: 10.1007/s11899-025-00752-3.
This report summarizes key insights from the 8th Annual International Symposium on Myeloproliferative Neoplasms (MPN Asia 2025). The symposium brought together global experts to discuss advancements in MPN biology, diagnostics, and therapeutics, with a focus on emerging molecular understanding, novel treatment strategies and real-world data.
Molecular profiling has become essential in MPN risk stratification and therapeutic decision-making. High-risk mutations (e.g., ASXL1, TP53) and inflammatory pathways (e.g., IL-17, NF-κB) were shown to correlate with disease progression and transformation. Interferon-based therapy is increasingly used in younger, low-risk, or treatment-naïve patients, and is also being investigated in myelofibrosis and essential thrombocythemia. Ropeginterferon alfa-2b, a novel interferon-based therapy, demonstrated durable clinical efficacy in polycythemia vera. Its high initial-dose and accelerated titration (HIDAT) regimen led to fast achievement of complete hematologic response, rapid reductions in JAK2V617F allele burden, and high complete molecular response rate. Combination regimens involving ruxolitinib and agents such as pelabresib, selinexor, and interferon showed potential for enhanced efficacy. Population-based studies from Asia contributed regional epidemiological and treatment data, reinforcing the role of real-world evidence. Modern prognostic models such as MIPSS70+ v2.0 and GIPSS were discussed for more precise risk prediction. Preliminary findings also suggest ropeginterferon alfa-2b may be a safe option during pregnancy. MPN Asia 2025 highlighted the growing role of molecular diagnostics and targeted therapeutics in the management of MPNs. Ropeginterferon alfa-2b has emerged as a therapeutic potential across the MPN spectrum. Its early use and personalized strategies are increasingly recognized. Real-world data and regional insights are shaping a more nuanced, globally informed approach to MPN care.
本报告总结了第八届骨髓增殖性肿瘤年度国际研讨会（MPN Asia 2025）的关键见解。该研讨会汇聚了全球专家，讨论骨髓增殖性肿瘤生物学、诊断和治疗方面的进展，重点关注新出现的分子认识、新型治疗策略和真实世界数据。
分子谱分析在骨髓增殖性肿瘤风险分层和治疗决策中变得至关重要。高风险突变（如ASXL1、TP53）和炎症途径（如IL-17、NF-κB）与疾病进展和转化相关。基于干扰素的治疗越来越多地用于年轻、低风险或未接受过治疗的患者，并且也正在骨髓纤维化和原发性血小板增多症中进行研究。聚乙二醇化干扰素α-2b是一种新型的基于干扰素的治疗方法，在真性红细胞增多症中显示出持久的临床疗效。其高初始剂量和加速滴定（HIDAT）方案导致快速实现完全血液学缓解、JAK2V617F等位基因负担迅速降低以及高完全分子缓解率。涉及芦可替尼和诸如派拉布瑞西、塞利尼索和干扰素等药物的联合方案显示出增强疗效的潜力。来自亚洲的基于人群的研究提供了区域流行病学和治疗数据，加强了真实世界证据的作用。讨论了诸如MIPSS⁷⁰⁺ v2.0和GIPSS等现代预后模型以进行更精确的风险预测。初步研究结果还表明聚乙二醇化干扰素α-2b在怀孕期间可能是一种安全的选择。MPN Asia 2025强调了分子诊断和靶向治疗在骨髓增殖性肿瘤管理中日益重要的作用。聚乙二醇化干扰素α-2b已成为整个骨髓增殖性肿瘤谱系中的一种治疗潜力。其早期使用和个性化策略越来越受到认可。真实世界数据和区域见解正在塑造一种更细致入微、全球知情的骨髓增殖性肿瘤护理方法。
